Cancer Drug Spending Is Headed Past $400 Billion as Colorectal and Pancreatic Cancers Move Up the Research Agenda
Global cancer drug spending reached $252B in 2024 and is forecast to exceed $400B by 2028, with the U.S. accounting for 46%. Several companies, including Oncolytics Biotech (ONCY), Revolution Medicines (RVMD), Eli Lilly (LLY), Genmab (GMAB), and Exelixis (EXEL), are advancing treatments for colorectal and pancreatic cancers. Oncolytics reported accelerating enrollment in a colorectal cancer study, while Revolution Medicines received FDA approval for a pancreatic cancer drug.
How this was made
The 30-second read
Why it matters
Collectively, the news underscores a wave of new oncology therapies entering late‑stage development, which could lift the broader biotech sector but also introduces volatility around each company's specific milestones.
Market read
Biotech stocks may react to upcoming trial data and regulatory updates; investors should monitor interim readouts and FDA timelines.
What to watch
Potential competition from other RAS inhibitors and payer reimbursement uncertainties could limit upside.
Background
The article surveys recent FDA approvals, trial readouts, and pipeline progress across several oncology biotech firms.
Ticker impact
Oncolytics announced accelerated enrollment in its Phase 2 colorectal cancer trial and expects interim data by year‑end.
likely upward pressure as investors price in upcoming interim results
Enrollment acceleration signals trial momentum; early read‑out often moves biotech shares.
Revolution Medicines disclosed FDA approval of RASONQUE for metastatic pancreatic cancer and plans to share colorectal data in Q4 2026.
moderate upside ahead of Q4 data release
Approval is already priced, but future data could drive further moves.
Eli Lilly received FDA approval for Jaypirca in chronic lymphocytic leukemia, citing an 80% risk reduction.
slight upward pressure as market digests expanded label
Approval adds incremental sales potential; impact modest relative to Lilly size.
Genmab and AbbVie reported Phase 3 EPCORE DLBCL‑2 trial met primary endpoint, reducing progression risk by 51% in DLBCL.
potential upside as investors anticipate commercial rollout
Phase 3 success is material for biotech, though impact may be shared with partner.
Exelixis said the FDA extended its review of zanzalintinib for metastatic colorectal cancer by three months after a major amendment.
likely downward pressure until next review milestone
Extension signals regulatory concerns, which typically depress biotech shares.
Market effects
Highlights accelerating pipeline activity in oncology, may boost sector sentiment.
U.S. biotech sector could see modest inflows as investors chase trial updates.
European partners (Genmab) also benefit, reinforcing cross‑border oncology collaborations.
Counterpoint
Recent approvals may already be priced; upcoming data could disappoint, leading to sell‑offs.
Key entities
- companyOncolytics Biotech
Biotech developing pelareorep immunotherapy.
- companyRevolution Medicines
Developer of RASONQUE for pancreatic cancer.
- companyEli Lilly
Pharma with new BTK inhibitor approval.
- companyGenmab
Partner in epcoritamab DLBCL trial.
- companyExelixis
Company with extended FDA review for colorectal cancer combo.
